Alimera Announces Agreement With Jaeb Center For Health Research On Behalf Of The DRCR Retina Network To Support And Provide Iluvien 0.19 Mg Sustained Release Intravitreal Implant

ATLANTA, Sept. 23, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned

ATLANTA, Sept. 23, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (NASDAQ:ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that it has entered into an agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), acting on the behalf of the DRCR Retina Network to support and provide ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for “A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy (Protocol AL)”.

The study, which is expected to begin in Q1 2023, is planned to include 600 participants with primary choroidal melanoma receiving treatment with plaque brachytherapy. The study will assess development of macular edema and associated long-term visual acuity effects of consistent and continuous release of corticosteroid or repeated injections of anti-VEGF initiated near the time of radiation therapy compared to observation until macular edema develops in patients at risk for radiation retinopathy.

“We are very excited to be working with this prestigious network of physicians in evaluating ILUVIEN’s potential to address another unmet need affecting the retina,” said Rick Eiswirth, President and Chief Executive Officer of Alimera. “When utilized as baseline therapy, as in our New Day Study (NCT04469595) for diabetic macular edema, we believe ILUVIEN’s CONTINUOUS MICRODOSING™ delivery may prevent, delay or reduce the occurrence of the complication of radiation retinopathy and consequent vision loss when used in patients treated with plaque brachytherapy.”

Total
0
Shares
Related Posts